Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first healthy volunteer has been dosed in a Phase 1 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. The Company believes TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome (ARDS).

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the publication of a peer-reviewed paper summarizing positive results from completed Phase 1 clinical and preclinical studies of TD-1473, the Company's gut-selective pan-Janus kinase (JAK) inhibitor. The manuscript, which was published in the Journal of Crohn's and Colitis, highlights a broad collection of data demonstrating minimal systemic drug exposure, local target engagement, and trends toward reduced markers of ulcerative colitis disease activity following TD-1473 administration versus placebo.

Q4 2019 Theravance Biopharma Inc Earnings Call

Q1 2020 Theravance Biopharma Inc Earnings Call

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Renowned guru slims position in biotech company that focuses on kidney disease Continue reading...

Baupost leader is also seeking more capital Continue reading...

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance Biopharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

TBPH earnings call for the period ending March 31, 2020.

A week ago, Theravance Biopharma, Inc. (NASDAQ:TBPH) came out with a strong set of full-year numbers that could...

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and provide a business update after market close on Wednesday, May 6, 2020. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m. ET (2:00 p.m. PT/9:00 p.m. GMT) that day.

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with Acute Lung Injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to Acute Respiratory Distress Syndrome (ARDS).

Rick Winningham became the CEO of Theravance Biopharma, Inc. (NASDAQ:TBPH) in 2014. This analysis aims first to...

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes. The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta. The Company used a portion of the net proceeds from this transaction to repay in full the remaining outstanding balance of the $250 million Triple PhaRMASM 9.0% fixed rate term notes due 2033 and intends to use the remainder of the net proceeds to support continued execution of its key development programs.

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.